ExpreS2ion Biotech Holding AB (publ) announced that the remaining virus neutralization data, for the two dose ranges of 50 ?g and 70 ?g, have now been published from the COUGH-1 COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine. The headline results met its safety and efficacy endpoints also for these dose ranges, and thus for the study in its entirety. Positive initial data from the first-in-human study of ABNCoV2, the capsid virus like particle (cVLP) COVID-19 vaccine candidate licensed from ExpreS2ion's joint venture partner AdaptVac, was announced on August 9, 2021, and the remaining data for the high dose groups have now become available. The results demonstrate that the vaccine was well tolerated across all dose groups, with no observed difference in the adverse event profile after first and second vaccinations. No serious adverse events were reported, and the safety profile was comparable to other vaccines based on recombinant protein-technology. In all dose groups, antibody titers were boosted after the second vaccination to levels significantly higher than those reported for current approved COVID-19 vaccines. Titers were up to 12-fold higher than those measured in convalescent human samples with similar strong responses seen across the groups receiving 25, 50 and 70 ?g, indicating a plateau within this range. This could potentially provide rationale for reducing the dose of the vaccine while maintaining optimal effect. Importantly, ABNCoV2 demonstrated high neutralization titers against all SARS-CoV-2 variants of concern, including the dominant Delta and escape variant Beta. Bavarian Nordic continues its Phase II trial to evaluate ABNCoV2 as a booster vaccine for individuals with previous COVID-19 disease or vaccination, expecting headline data before end of the year. In parallel, Bavarian Nordic is preparing for ABNCoV2 to be investigated during 2022 in a Phase III trial, which as previously announced has obtained funding from the Danish State.